cMAP4K2 acted as miR-377 sponge to affect the biological activity of miR-377, which led to increased expression of vascular endothelial growth factor A (VEGFA).
Targeting circRNA-MAP4K2 for the treatment of diabetes-induced retinal vascular dysfunction.